Small caps

Bradley Hunnewell, CFA Joins Boston Trust Walden as a Portfolio Manager

Retrieved on: 
Tuesday, October 10, 2023
Rothschild & Co, Rothschild, Rockefeller Capital Management, Market capitalization, Small, Research, Small caps, Bank

BOSTON, Oct. 10, 2023 /PRNewswire/ -- Boston Trust Walden is pleased to announce that Bradley Hunnewell has joined the firm.

Key Points: 
  • BOSTON, Oct. 10, 2023 /PRNewswire/ -- Boston Trust Walden is pleased to announce that Bradley Hunnewell has joined the firm.
  • He will serve as a portfolio manager and securities research analyst on the Small Cap and SMID Cap Equity strategy teams.
  • Mr. Hunnewell previously served as a Director and Portfolio Manager of Small & Mid Cap Equities at Rothschild & Co US Asset Management for three years.
  • "We are thrilled to welcome Brad to Boston Trust Walden," said Chief Investment Officer and co-Chief Executive Officer Stephen Amyouny.

Diabeloop - Key Player in Therapeutic AI Applied to Insulin Delivery - Announces 70 Million Euros New Financing Round to Accelerate Its International Expansion

Retrieved on: 
Thursday, June 2, 2022
Digital health, White knight, AID, Small caps, Glucose meter, Hearing, Telehealth, Artificial intelligence, Real, CEO, CGM, Partnership, Refuge du Promontoire, Lapillus, Algorithm, CE, Conditional sentence, Diabetes, Disease, AGIR, Newstone Capital Partners, Solution, Digital, Type 1, Growth, GLOBE, Patient, Venture round, Quality of life, Personality, UI, Board, White Stone, Medical device, Fine chemical, Pharmaceutical industry, Financial services, Venture

The first closed-loop solutions commercialized by Diabeloop offer personalized management for Type 1 (DBLG1) and highly unstable Type 1 diabetes (DBL-hu).

Key Points: 
  • The first closed-loop solutions commercialized by Diabeloop offer personalized management for Type 1 (DBLG1) and highly unstable Type 1 diabetes (DBL-hu).
  • By connecting a Continuous Glucose Monitoring device (CGM) and an insulin pump, Diabeloop's world-leading algorithms analyze data in real time and automate insulin delivery.
  • It transforms the lives of people with diabetes by taking over many of the therapeutic decisions that used to fall to patients.
  • Diabeloop just completed its Series C financing round, securing 70 million euros, to accelerate its commercial roll-out, support its sustained growth strategy and its high-impact projects.